Cite

HARVARD Citation

    Pizzuti, L. et al. (2018). Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer biology & therapy. 19 (4), pp. 328-334. [Online]. 
  
Back to record